What a new Alzheimer’s drug could mean for the future of treatment
After years of hits and misses trying to unlock the mysteries of Alzheimer’s disease, experts say recent research has yielded ...
New Scientist
Next-generation Alzheimer’s drug reduces risk of serious brain bleeds
A new kind of antibody drug that more efficiently enters the brain could slow the progression of Alzheimer's disease with a ...
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by ...
Biogen Shares Fall as Alzheimer’s Tau Trial Data Disappoint
Biogen Inc. shares declined after additional data from a mid-stage study of its Alzheimer’s drug diranersen failed to show ...
KRAS-targeting drugs show promise for rare appendix cancer
Targeting mutant KRAS may offer a promising new treatment option for appendix cancer, according to research from The ...
The Diplomat
USS Ronald Reagan Drug Case Raises Questions About Off-Base Reach in Japan
Publicly released U.S. Navy court records reviewed by The Diplomat show that a drug distribution case aboard the aircraft carrier USS Ronald Reagan may have extended beyond the ship and into off-base ...
The Business Journals
Controversial drug at center of multibillion-dollar Amgen deal faces more questions after paper retracted
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA in January sent the ...
Morningstar
Sanofi Drug for Rare Neuromuscular Disease Hits Goals in Late-Stage Trial
Sanofi said its Nexviazyme drug met primary and secondary objectives in a late-stage clinical trial for the most aggressive variant of a rare neuromuscular condition called Pompe disease. The French ...
Reuters
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings
June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s (AMGN.O), opens new tab rare-disease drug, citing ...
Yahoo
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings
Add Yahoo as a preferred source to see more of our stories on Google. The Amgen logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration June 29 (Reuters) - The New ...
Hosted on MSN
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings
June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns that patient ...
Bloomberg L.P.
Amgen Drug Tavneos’ Main Study Retracted by Medical Journal
A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, putting the drug’s continued sales at risk. Two of the study’s authors ...